迷你Hyper-CVD联合维奈克拉治疗复发/难治性急性淋巴细胞白血病的1/2期研究
这项1/2期试验评估低强度化疗迷你Hyper-CVD联合维奈克拉在成人复发/难治性急性淋巴细胞白血病中的安全性和疗效,共治疗22例患者,推荐的2期剂量为维奈克拉每日400 mg,复合完全缓解率为57%,中位总生存期为7.1个月,1年总生存率为29%。
要点
- 维奈克拉联合方案的推荐2期剂量为每日400 mg。
- 复合完全缓解率为57%(完全缓解43%,伴不完全血液学恢复的完全缓解14%)。
- 中位缓解持续时间6.3个月,中位总生存期7.1个月,1年总生存率29%。
核心结论
- 迷你Hyper-CVD联合维奈克拉在经过 heavily 治疗的复发/难治性急性淋巴细胞白血病中具有活性,需要进一步开发基于维奈克拉的联合方案。
研究设计与样本
- 1/2期临床试验,评估低强度化疗联合维奈克拉在成人复发/难治性急性淋巴细胞白血病中的安全性和疗效,共治疗22例患者。
主要发现
- 既往治疗中位数为2线(范围1-6线);13例(59%)曾接受异基因造血干细胞移植;18例B细胞急性淋巴细胞白血病患者中7例(39%)既往接受过奥英妥珠单抗和贝林妥欧单抗。
- 维奈克拉在联合方案中的推荐2期剂量为每日400 mg。
- 复合完全缓解和伴不完全血液学恢复的完全缓解率为57%(完全缓解43%,伴不完全血液学恢复的完全缓解14%),45%的缓解者通过多参数流式细胞术达到可测量残留病阴性。
- 4例患者后续接受异基因造血干细胞移植;中位缓解持续时间6.3个月;中位总生存期7.1个月,1年总生存率29%。
- 最常见的≥3级非血液学不良事件为感染17例(77%)和发热性中性粒细胞减少4例(18%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical studies suggest that Bcl-2 inhibition with venetoclax has antileukemic activity in acute lymphoblastic leukemia (ALL) and may synergize with conventional chemotherapy. We designed a phase 1/2 clinical trial to evaluate the safety and efficacy of low-intensity chemotherapy in combination with venetoclax in adults with relapsed or refractory ALL. Patients received the mini-hyper-CVD regimen (dose-attenuated hyperfractionated cyclophosphamide, vincristine, and dexamethasone alternating with methotrexate and cytarabine) in combination with venetoclax (200 mg or 400 mg daily) on days 1 to 14 in cycle 1 and on days 1 to 7 in consolidation cycles. Twenty-two patients were treated. The median number of prior therapies was 2 (range, 1-6). Thirteen patients (59%) had undergone prior allogeneic stem cell transplant (allo-SCT), and 7 of 18 patients (39%) with B-cell ALL had previously received both inotuzumab ozogamicin and blinatumomab. The recommended phase 2 dose of venetoclax in the combination regimen was 400 mg daily. The composite complete remission (CR) and CR with incomplete hematologic recovery (CRi) rate was 57% (CR, 43%; CRi, 14%), and 45% of responders achieved measurable residual disease negativity by multiparameter flow cytometry. Four patients proceeded to allo-SCT. The median duration of response was 6.3 months. The median overall survival was 7.1 months, and the 1-year overall survival rate was 29%. The most common grade ≥3 nonhematologic adverse events were infection in 17 patients (77%) and febrile neutropenia in 4 patients (18%). Overall, the combination of mini-hyper-CVD plus venetoclax was active in heavily pretreated relapsed/refractory ALL. Further development of venetoclax-based combinations in ALL is warranted. This trial is registered at www.clinicaltrials.gov as #NCT03808610.
引用
- Short NJ, Jabbour E, Jain N, et al. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2024. PMID: 38207208. doi:10.1182/bloodadvances.2023012231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。